Clinical observation of Shenqi Gushen decoction combined with empagliflozin in the treatment of type 2 diabetic kidney disease patients with G3aA2 stage
Objective To explore the clinical effect of Shenqi Gushen decoction combined with Empagliflozin in treating type 2 diabetic kidney disease patients with G3aA2 stage.Methods Sixty patients of type 2 diabetic kidney disease patients with G3aA2 stage came from the department of endocrinology,Lu'an Hospital of Traditional Chinese Medicine between February 2022 and December 2023.They were equally divided into control group and Observation Group.Every group of patients should be given dietary intervention,effective control of blood glucose and blood pressure,lipid regulation and so on.All the patients in the control group and the observation group took Empagliflozin orally.The patients in the observation group were given Shenqi Gushen decoction again.The changes of creatinine(Cr),estimated glomerular filtration rate(eGFR),Urinary retinol-binding protein(URBP),Urinary N-acetyl-β-D-glucosaminidase(UN-AG),β2-microglobulin(β2-MG),UACR and TCM syndrome integral in each group were recorded in detail.Results The Observation Group was more prominent than the control group in clinical efficacy.Inter-group comparison:the Ob-servation Group(Cr,URBP,UNAG,β2-MG,UACR,TCM syndrome score)decreased(P＜0.05),eGFR increased,more than those in the control group(P＜0.05).Intra-group comparison:After treatment,the levels of(URBP,UNAG and β2-MG)in the control group were significantly lower than those before treatment(P＜0.05).After treatment in the Observation Group(Cr,URBP,UNAG,β2-MG,UACR,TCM syndrome score)decreased and eGFR increased signifi-cantly(P＜0.05).Conclusion Shenqi Gushen decoction combined with Empagliflozin has a better effect in treating patients with diabetic kidney disease G3aA2 stage.
维普
万方数据
